Clinical Scorecard: Clinical Features and Survival Rates of TFE3-Rearranged Renal Cell Carcinoma: A Retrospective Analysis Compared to Clear Cell Renal Cell Carcinoma Using Propensity Score Matching

At a Glance

Key Highlights

• TFE3-rRCC diagnosis is challenging due to heterogeneous morphology and overlapping immunophenotypes with other RCC subtypes.
• TFE3 break-apart FISH is the most sensitive and specific confirmatory test for detecting TFE3 rearrangements.
• Clinical behavior varies; some studies show aggressive course and advanced stage at presentation, while others report outcomes comparable to clear-cell RCC.

Guideline-Based Recommendations

Diagnosis

• Perform TFE3 break-apart FISH testing when clinical, morphological, or immunohistochemical features suggest TFE3-rRCC.
• Use TFE3 immunohistochemistry as a screening tool but confirm with FISH due to limited specificity.
• Consider RNA-based or next-generation sequencing fusion testing if FISH is negative but suspicion remains high.

Management

• Surgical resection remains the primary treatment; partial nephrectomy may be considered for localized tumors, though evidence is limited.
• Radical nephrectomy is commonly performed, especially for higher stage tumors.
• Selective lymph node dissection is advised for suspicious nodes.

Monitoring & Follow-up

• Regular follow-up with imaging and clinical assessments to detect recurrence or metastasis.
• Monitor overall survival and progression-free survival post-surgery.

Risks

• Potential for advanced stage at diagnosis and aggressive clinical course in some patients.
• Diagnostic challenges may delay appropriate treatment.

Patient & Prescribing Data

Patients diagnosed with TFE3-rRCC undergoing surgical treatment at a tertiary care center.

Approximately 56.5% underwent radical nephrectomy and 43.5% partial nephrectomy; partial nephrectomy was mostly performed in T1a tumors with some T1b and rare T3a cases.

Clinical Best Practices

• Use a combination of clinical, morphological, and immunohistochemical criteria to select cases for TFE3 FISH testing.
• Apply propensity score matching in retrospective analyses to minimize confounding when comparing TFE3-rRCC with ccRCC.
• Consider nephron-sparing surgery cautiously in early-stage TFE3-rRCC pending further evidence.

References

• WHO Classification of RCCs 2022
• TFE3 FISH Testing in RCC Diagnosis
• Propensity Score Matching in RCC Studies